Loading articles...
Why Cheaper Humira Alternatives Face Resistance
Adalimumab biosimilars cut NHS spend by over 50% while treating more patients. NOR-SWITCH and subsequent trials consistently show switching from reference biologic to biosimilar is safe. Sarah Mitchell and James Carter explain the regulatory science, the no...
Stopping Spinal Fusion Or Protecting The Gut?
PsA is not RA with skin, and axSpA is not RA in the spine. The biologic hierarchy shifts significantly across the spondyloarthropathy spectrum - IL-17 and IL-23 inhibitors dominate, anti-TNF has uveitis caveats, and IBD comorbidity changes everything. Sarah...
Chasing Absolute Zero In Rheumatoid Arthritis
Treat-to-target transformed RA outcomes - not through new drugs but through rigorous measurement and escalation discipline. Sarah Mitchell and James Carter cover the evidence base, the disease activity tools, the window of opportunity in early RA, and when ...
The ORAL Surveillance JAK Inhibitor Controversy
ORAL Surveillance showed tofacitinib carried higher cardiovascular and malignancy risk than anti-TNF in high-risk RA patients - triggering a class-wide boxed warning. But was the signal overgeneralised? Sarah Mitchell and James Carter unpack the data, the c...
RA Patients Face Elevated Fracture Risk: EULAR 2026 Highlights
Rheumatoid arthritis (RA) significantly increases fracture risk beyond traditional factors. EULAR 2026 data underscores the need for early bone health assessment.
EULAR 2026: Polymyalgia Rheumatica Guidelines Incorporate RWE
EULAR 2026 guidelines for polymyalgia rheumatica (PMR) integrate real-world evidence (RWE), refining diagnostic and treatment algorithms.
EULAR 2026: Methotrexate Remains Cornerstone in RA First-Line
EULAR 2026 reaffirms methotrexate's central role in first-line rheumatoid arthritis therapy, with new data on optimal dosing and combination strategies.
RA Treatment Optimisation: Applying Two Decades of Progress
EULAR 2026 highlights the evolution of rheumatoid arthritis management, emphasising early, aggressive intervention and treat-to-target strategies.
EULAR 2026: Key Rheumatology Trials to Watch
Anticipated trials at EULAR 2026 will address unmet needs in psoriatic arthritis and systemic lupus erythematosus, focusing on novel therapeutic targets.
Early Intervention Crucial for Inflammatory Joint Disease, Osteoporosis
EULAR 2026 highlights the imperative of early diagnosis and intervention in inflammatory joint diseases and osteoporosis to prevent irreversible damage.